



FOR IMMEDIATE RELEASE
August 15, 2017

CONTACT: Peter Demakos
pdemakos@stimmed.com

StimMed announces 2nd FDA Indication for Use approval

BUFFALO, NY - StimMed, LLC a Western New York medical device company announced today it has received an additional FDA approval for its StimSox product.

This new approval is for ***“immediate post-surgical stimulation of calf muscles to prevent venous thrombosis”***. The system had already been approved to ***“temporarily increase local blood circulation in healthy leg muscles”***.

Peter Demakos, StimMed CEO stated “this is significant, and a great step in enhancing the value of the product for use in a wider range of applications.”

The device was designed to promote blood flow by electrically stimulating the foot muscles and by doing so, potentially preventing blood clots. It has been shown that poor leg circulation can result in a Deep Vein Thrombosis (DVT) which causes as many as 100,000 deaths per year. DVT is also a cause of costly patient hospital readmission. The device has potential uses during certain surgical procedures, for post-surgical care as well as rehabilitation patients.

Demakos also noted that the product redesign is progressing as scheduled with the new Alpha prototype recently completed. This version will cost much less to manufacture and be easier for patients to use. The goal is to have the final tested product complete around the end of Q4 2017.

Gregg Gellman, StimMed COO stated that “this expanded indication for use from FDA increases StimMed ability to provide a cost effective portable medical device that enhances positive clinical outcomes and improves patient care for people at risk or poor circulation and venous thrombosis”.

StimMed, LLC
388 Evans Street
Buffalo, New York 14221
1-800-STIMMED
www.stimmed.com